

Docket No. 19442-2063.01

1c978 U.S. PTO
09/920480
08/01/01

Express Mail Label No.: EL548 626 398US

Certificate of Mailing by "Express Mail"

Date of Deposit: August 1, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Dated: 8/1/01

Name: Edgar Benavides

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Charles A. Nicolette

Filing Date: Herewith

Serial No.: Unassigned

Title: MELANOMA ANTIGENIC PEPTIDES

Assignee: Genzyme Corp.

Examiner: Unassigned

Group Art Unit: Unassigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- ☒ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- ☐ Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

08/1/01 02:53 PM

This Information Disclosure Statement is filed:

- ☐ After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.[] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

This Information Disclosure Statement is filed:

- ☐ After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

II. Copies of the Cited Items:

- ☐ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
- ☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed: _____.
- ☒ Copies of all items in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No.: 09/249,272, filed February 11, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).

- ☐ Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

- ☒ A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
- ☐ A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

IV. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
 2. a representation that a search has been made, other than as described above;
- or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 Docket No.: 19442-203601 for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: August 1, 2001

Respectfully submitted,

By: Antoinette F. Konski

Antoinette F. Konski

Registration No.: 34,202

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111
Telephone: (650) 849-4400
Telefax: (650) 849-4800

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 159792006300		Application Number 09/249,272	
				Applicant Charles A. NICOLETTE			
				Filing Date February 11, 1999		Group Art Unit 1648	

PTO
09/920460
08/01/01

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	03/20/97	WO 97/35035	Nicolette			

OTHER DOCUMENTS			(including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title	
	2.	Alexander-Miller et al., "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" <i>PNAS USA</i> 93(9):4102-4107 (1996).	
	3.	Bloom et al., "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16 melanoma" <i>J. Exp. Med.</i> 185(3):453 (1997).	
	4.	Borchardt et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" <i>Chem. Biol.</i> 4(12):961-968 (1997).	
	5.	Bouchard et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells" <i>Eur. J. Biochem.</i> 219(1-2):127-134 (1994).	
	6.	Colaco, "Why are dendritic cells central to cancer immunotherapy?" <i>Mol. Med. Today</i> :14-17 (January 1999).	
	7.	Gish et al., "Identification of protein coding regions by database similarity search" <i>Nature Genetics</i> 3:266-273 (1993).	
	8.	Kawakami et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" <i>PNAS USA</i> 91(9):3515-3519 (1994).	
	9.	Kawakami et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS USA</i> 91:6458-6462 (1994).	
	10.	Lindauer et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" <i>J. Mol. Med.</i> 76:32-47 (1998).	
	11.	Pardoll, "Cancer vaccines" <i>Nature Med. Vaccine Supp.</i> 4(5):525-531 (May 1998).	

EXAMINER:	DATE CONSIDERED:
------------------	-------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 159792006300	Application Number 09/249,272
	Applicant Charles A. NICOLETTE	
	Filing Date February 11, 1999	Group Art Unit 1648

OTHER DOCUMENTS	<i>(including author, title, Date, Pertinent Pages, Etc.)</i>
------------------------	---

Examiner Initials	Ref. No.	Title
	12.	Rosenberg et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" <i>Nature Med.</i> 4(3):321-327 (1998).
	13.	Salgaller et al. "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides" <i>Cancer Res.</i> 55:4972-4979 (1995).
	14.	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" <i>PNAS USA</i> 93:10614-10619 (1996).
	15.	Shepherd et al., "Preparation and screening of an arrayed human genomic library generated with the P1 cloning system" <i>PNAS USA</i> 91:2629-2633 (1994).
	16.	Tam, "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system" <i>PNAS USA</i> 85:5409-5413 (1998).
	17.	Türeci et al., "Serological analysis of human tumor antigens: Molecular definition and implications" <i>Mol. Med. Today</i> 3(8):342-349 (August 1997).
	18.	Zhai et al., "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100" <i>J. Immunol.</i> 20(1):15-25 (1997).
	19.	Zügel et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" <i>J. Immunol.</i> 161:1705-1709 (1998).

--

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	